<DOC>
	<DOCNO>NCT02920021</DOCNO>
	<brief_summary>The purpose study determine ANB020 safety , tolerability activity adult patient peanut allergy .</brief_summary>
	<brief_title>Placebo-Controlled Study Investigate ANB020 Activity Adult Patients With Peanut Allergy</brief_title>
	<detailed_description>This single center , randomize , double-blind , placebo-controlled , proof concept study assess safety tolerability ANB020 adult patient peanut allergy .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Male female patient age &gt; 18 year able give inform consent . Patients confirm clinically allergic response peanut . Positive peanut allergy skin prick test &gt; 3 mm negative control detectable serum peanutspecific Immunoglobulin E ( IgE ) level ImmunoCAP test . Body mass index ( BMI ) 18 32 kg/m2 ( inclusive ) total body weight &gt; 50 kg ( 110 lb ) . BMI = weight ( kg ) / ( height [ m2 ] ) . Willing able comply study protocol requirement . Have ability read understand study procedure ability communicate meaningfully Investigator staff . Women childbearing potential , must negative serum pregnancy test screen Day 1 , surgically sterile use acceptable method contraception throughout study 15 week last administration investigational product . Postmenopausal patient define ( 1 ) age 45 year least 1 year amenorrhea level follicle stimulate hormone 20 IU/L ( 2 ) age 50 year least 1 year amenorrhea . Male patient must willing use effective method contraception entire study period 15 week last administration investigational product . Have concomitant dermatological medical condition ( ) may interfere Investigator 's ability evaluate patient 's response investigational product . Have experience severe lifethreatening anaphylactic reaction peanut ( i.e. , require hospitalization ) . Participation interventional study treatment peanut and/or food allergy 12 month screen . Have receive investigational product part interventional clinical study within period 3 month 5 halflives ( whichever longer ) screen . Have receive systemic corticosteroid , nonsteroidal , immunosuppressant , immunomodulating drug treatment within 8 week screen . Use beta blocker , angiotensinconverting enzyme inhibitor , angiotensinreceptor blocker , calcium channel blocker within 4 week screen . History ischemic cardiovascular disease . Use biologics unconventional allergen immunotherapy within 12 month screen . Have receive antibiotic treatment within 1 week screening . Have history hypersensitivity allergic reaction follow infusion human blood blood component . Have history hypersensitivity allergic reaction component ANB020 formulation inactive ingredient ( excipients ) . If female , pregnant lactating , intend become pregnant study period . Current diagnosis asthma require Global Initiative Asthma Assessment ( GINA ) Step 3 high treatment asthma partially control uncontrolled accord GINA classification last three month screen ( Appendix I ) . History life threaten asthma attack ( example : require intensive care unit admission , intubation mechanical ventilation ) . Other significant medical condition opinion Principal Investigator , prevent participation study History drug , alcohol substance abuse , factor limit ability cooperate comply study protocol . Have physical , mental , medical condition , opinion Investigator , make study participation inadvisable could confound study assessment . Receipt live attenuate vaccine within 4 week screen . Planned surgery study 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>